Abstract
Measurement of antibody titres to the human polyomaviruses BK and JC has for many years had to rely on Hemagglutination inhibition. In recent years, viral serology based on virus-like particles (VLPs) in enzyme immunoassays (EIAs) has become widely used for a variety of viruses. We sought to establish a modern method for serological diagnosis of BK and JC viruses, by using purified VLPs containing the VP1 major capsid proteins. Antibody titres in assays based on VLPs of BKV (strain SB) showed no correlation to the titres in similar JCV assays. BKV (SB) seropositivity increases rapidly with increasing age of the children and reaches a 98 % seroprevalence at 7–9 years of age, whereas JCV seroprevalences increase more slowly with increasing age reaching 51% positivity among children 9–11 years of age. The antibody levels are almost identical in serial samples taken up to 5 years apart, suggesting that both BKV and JCV VLP seropositivitities are usually stable over time and can be used to measure cumulative exposure to these viruses.
Serology using SV40 VLPs showed strong cross-reactivity with human polyomaviruses, in particular with BKV strain AS, and establishing a specific VLP-based serology assay for SV40 required blocking with several hyperimmune sera to the human polyomaviruses. SV40-specific seropositivity also increased with increasing age of children, reaching 14% seroprevalence among children 7–9 years of age, but had limited stability over time in serial samples.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hamilton RS, Gravell M, Major EO. Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J Clin Microbiol 2000; 38(1):105–109.
Knowles WA, Pipkin P, Andrews N et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003; 71(1):115–123.
Jafar S, Rodriguez-Barradas M, Graham DY et al. Serological evidence of SV40 infections in HIV-infected and HIV-negative adults. J Med Virol 1998; 54(4):276–284.
Stolt A, Sasnauskas K, Koskela P et al. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003; 84 (Pt 6):1499–1504.
Sasnauskas K, Buzaite O, Vogel F et al. Yeast cells allow high-level expression and formation of polyomavirus-like particles. Biol Chem 1999; 380(3):381–386.
Gedvilaite A, Frommel C, Sasnauskas K et al. Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. Virology 2000; 273(1):21–35.
Jin L, Gibson PE, Booth JC et al. Genomic typing of BK virus in clinical specimens by direct sequencing of polymerase chain reaction products. J Med Virol 1993; 41(1):11–17.
Jin L, Gibson PE, Knowles WA et al. BK virus antigenic variants: Sequence analysis within the capsid VP1 epitope. J Med Virol 1993; 39(1):50–56.
Shah KV. Polyomaviruses. 3rd ed. Philadelphia: Lipincott-Raven, 1996.
af Geijersstam V, Eklund C, Wang Z et al. A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children. Int J Cancer 1999; 80(4):489–493.
Butel JS, Lednicky JA. Cell and molecular biology of simian virus 40: Implications for human infections and disease. J Natl Cancer Inst 1999; 91(2):119–134.
Minor P, Pipkin P, Jarzebek Z et al. Studies of neutralising antibodies to SV40 in human sera. J Med Virol 2003; 70(3):490–495.
Vilchez RA, Kozinetz CA, Butel JS. Conventional epidemiology and the link between SV40 and human cancers. Lancet Oncol 2003; 4(3):188–191.
Padgett BL, al DL We. Cultivation of papovalike virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1971; 1:1257–1260.
Hogan TF, Padgett BL, Walker DL. Human polyomaviruses. In: Belshe RB, ed. Textbook of Human Virology, 1991.
af Geijersstam V, Kibur M, Wang Z et al. Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 1998; 177(6):1710–1714.
Kibur M, af Geijerstamm V, Pukkala E et al. Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination. Sex Transm Infect 2000; 76(1):13–17.
Neel JV, Major EO, Awa AA et al. Hypothesis: “Rogue cell”-type chromosomal damage in lymphocytes is associated with infection with the JC human polyoma virus and has implications for oncopenesis. Proc Natl Acad Sci USA 1996; 93(7):2690–2695.
Tornatore C, Berger JR, Houff SA et al. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol 1992; 31(4):454–462.
Arthur RR, Shah KV, Yolken RH et al. Detection of human papovaviruses BKV and JCV in urines by ELISA. Prog Clin Biol Res 1983; 105:169–176.
Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999; 9(6):423–430.
Hale AD, Bartkeviciute D, Dargeviciute A et al. Expression and antigenic characterization of the major capsid proteins of human polyomaviruses BK and JC in Saccharomyces cerevisiae. J Virol Methods 2002; 104(1):93–98.
Ou WC, Wang M, Fung CY et al. The major capsid protein, VP1, of human JC virus expressed in Escherichia coli is able to self-assemble into a capsid-like particle and deliver exogenous DNA into human kidney cells. J Gen Virol 1999; 80(Pt 1):39–46.
An K, Lovgren TR, Tilley MB et al. Use of the confocal microscope to determine polyomavirus recombinant capsid-like particle entry into mouse 3T6 cells. J Virol Methods 2000; 84(2):153–159.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Eurekah.com and Springer Science+Business Media
About this chapter
Cite this chapter
Lundstig, A., Dillner, J. (2006). Serological Diagnosis of Human Polyomavirus Infection. In: Ahsan, N. (eds) Polyomaviruses and Human Diseases. Advances in Experimental Medicine and Biology, vol 577. Springer, New York, NY. https://doi.org/10.1007/0-387-32957-9_7
Download citation
DOI: https://doi.org/10.1007/0-387-32957-9_7
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-29233-5
Online ISBN: 978-0-387-32957-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)